Melanotan II

Every batch ships with a batch code printed on the vial. The matching independent lab report — identity, purity, and composition — independently lab-tested results — is linked on the product page and also available from your order page after purchase.

We recommend it — especially if you are pregnant, nursing, managing a medical condition, or combining peptides with prescribed medication. Our product pages are educational. They are not medical advice and they do not replace a conversation with a qualified practitioner.

Orders placed before 14:00 CET Monday–Friday ship the same business day from our European fulfilment centre in The Hague, Netherlands. Standard tracked EU delivery arrives in 2–4 business days; express options are available at checkout.

Research-only means the compound has not been approved by the EMA or any national medicines authority for medical use, and is sold solely for in-vitro and laboratory research. It is not a supplement, a cosmetic, or a medicine, and it carries no claims for human consumption.

Melanotan II is not approved by the EMA, FDA, MHRA, or TGA, and regulators have issued consumer warnings citing unregulated supply chains and changes to existing moles. Case reports have described new or rapidly evolving naevi and isolated melanoma cases temporally linked to use, though causation is not established.

Honestly: it depends on the molecule. EMA-approved peptide drugs (semaglutide, tirzepatide, tesamorelin, thymalfasin in some jurisdictions) have multi-year safety datasets. Unapproved research peptides — BPC-157, TB-500, Melanotan II, Epithalon — have limited or no long-term human data.

A prescription peptide (e.g. Wegovy, Mounjaro, Vyleesi, Zadaxin in the relevant jurisdictions) has been through EMA or national-authority review, carries an authorised indication, and is dispensed by a pharmacy against a script. A research peptide is a reference-grade compound sold for laboratory use only.

Bring both the lyophilised vial and the bacteriostatic water to room temperature, equalise pressure with a sterile vented needle, then inject the solvent slowly down the side of the vial. Swirl gently — never shake — until clear, and refrigerate at 2–8 °C.

The calculation is peptide mass (mg) ÷ desired concentration (mg/mL) = volume of bacteriostatic water in mL. For example, a 5 mg vial at 1 mg/mL needs 5 mL; at 2 mg/mL, 2.5 mL. Every Peptyds product page carries a suggested reconstitution volume tuned to the vial size.

Most lyophilised peptides reconstituted with bacteriostatic water remain stable for 28–30 days at 2–8 °C, protected from light. A handful of short, fragile sequences — Epithalon among them — drop to roughly 14 days. Never freeze a reconstituted vial.

Across published trials and case series, the most frequent reported events are injection-site reactions (redness, induration, transient discomfort), headache, mild nausea, and temporary fatigue. GLP-1 and dual-agonist class peptides add dose-dependent gastrointestinal effects.

Peptides are not appropriate for anyone who is pregnant, nursing, planning conception, under 18, managing active cancer, or on immunosuppressants — and competitive athletes governed by WADA must avoid every peptide on the prohibited list. Anyone with a personal or family history of melanoma should specifically avoid melanocortin-receptor agonists.